Hearing loss gene therapy

N/A

Report date: 2024/12/09 20:01:07

Base Information

Drug NameHearing loss gene therapy
Drug Alias Name听力丧失基因治疗CGF-166
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionGene transferenceProtein atonal homolog 1 stimulants
TargetsProtein atonal homolog 1
Therapy Area/IndicationsHearing Loss
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsHearing Loss

Other Information

ATC CodeN/A
Related LinksN/A